Literature DB >> 6274066

Modulation of human T-cell differentiation markers by 12-O-tetradecanoylphorbol-13-acetate.

K Nagasawa, B E Chechik, E W Gelfand, S Sengupta, M Letarte, T W Mak.   

Abstract

The analysis of seven differentiation markers following incubation with the tumor promotor 12-O-tetradecanoylphorbol-13-acetate (TPA) was examined in the human leukemic T-cell line MOLT-3. Significant changes were observed in the activity of the markers terminal deoxynucleotidyl transferase (TdT). spontaneous proliferation and the ability of these cells to bind sheep erythrocytes. Levels of human thymus-leukemia-associated antigen (HThy-L) recently identified as a low molecular weight form of adenosine deaminase (ADA), were reduced by about 50%. No significant changes were observed in ecto-5'-nucleotidase [5'-NT) activities, in the proliferative response to PHA, or in the expression of IA-like antigens. These data and the time kinetics of the changes suggest that following incubation of these T-lymphoblasts with TPA there is a sequential loss of TdT, loss of the capacity for spontaneous proliferation, and the appearance of receptors for sheep erythrocytes. Subsequently there is a decrease in the level of HThy-L/ADA. This sequence appears to follow that proposed for prethymic precursor T-cell differentiation following activation with thymic epithelium.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6274066

Source DB:  PubMed          Journal:  Thymus        ISSN: 0165-6090


  2 in total

1.  12-O-Tetradecanoylphorbol-13-acetate (TPA) directly inhibits spontaneous immunoglobulin secretion by in vivo antigen-induced human lymphoblastoid B cells.

Authors:  J A Brieva; J S Louie; R H Stevens
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

2.  Activation of protein kinase C induces differentiation in the human T-lymphoblastic cell line MOLT-3.

Authors:  Y Yamauchi; K Nagasawa; T Mayumi; T Horiuchi; Y Niho
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.